The UK Budget

Autumn Budget backs UK life sciences growth and innovation through financing and faster regulatory pathways

Published on 20 November 2026

Research support and investment in NHS innovation create opportunities, but businesses face increased operating costs

Close up of stethoscope over a DNA data printout

At a glance

  • R&D support, broader financing options and employee incentives aim to help life sciences businesses innovate and scale.

  • Robotics and AI investment creates openings for suppliers that can demonstrate better patient outcomes and productivity.

  • VAT changes, higher minimum wages and recruitment constraints make early reviews of budgets, contracts and workforce plans essential.

The Autumn Budget 2026 has brought together more than £1 billion of public-private investment in life sciences, backed by almost £70 million in grants, as the government looks to support sector research and development (R&D), UK manufacturing and healthcare innovation. 

For pharmaceutical, biotech, medtech and care businesses, the measures could open up commercial opportunities for research partnerships and investment projects, alongside quicker regulatory pathways and adoption by the NHS.

Funding announcements are only part of the picture. Businesses will also need to assess changes to VAT, including the treatment of donated medicines, as well as founder incentives, international recruitment, sponsorship costs and the impact of higher minimum wages.

Building on these measures, a landmark financing announcement signals further investment in the sector’s infrastructure. The National Wealth Fund (NWF) announced on 16 November that it is committing £147 million to One North Quay at Canary Wharf as part of a £368.5 million debt financing package. NWF's first life sciences deal will fund the development and fit-out of specialist laboratory and technology R&D space, helping address capacity constraints and supporting innovative businesses as they scale in the UK. The project is due for completion in early 2028.

R&D

UK Research and Innovation will focus £1 billion over four years on priority innovation clusters aligned with the government's industrial strategy. Support will be targeted at university partnerships, proof-of-concept funding and plant and microbial science facilities.

As trailed before the Budget, the £165 million National AI Biosecurity Initiative will comprise £100 million for an AI Biosecurity Lab, £50.5 million for bio-surveillance and an initial £14.5 million for proof-of-concept development of novel medical countermeasures with industry. Diagnostics and biotechnology companies should consider whether their existing research could help detect or respond to emerging biological threats.

Improving regulatory speed

The Regulating for Growth Bill proposes new cross-economy powers that would temporarily adapt rules under strict safeguards to allow testing and scaling of new technologies, with a route to permanent change following successful trials. If enacted, these powers could allow businesses to test, refine and scale innovative products faster. Further details are due to be announced shortly. Businesses should monitor eligibility requirements and prepare evidence for future trials.

Healthcare funding, adoption and procurement

The government will allocate £100 million from the £300 million NHS Transformation Fund to accelerate robotic-assisted surgery in England. Its ambition is to increase annual procedures from around 70,000 to 500,000 by 2035, supported by a national robotics registry using data and AI.

An additional £80 million will support the Sovereign AI Fund’s challenge-led R&D procurement scheme, including solutions for health and care. The first annual AI challenge prize will focus on the NHS, with a top award of up to £2.5 million.

For medtech and digital health suppliers, these initiatives represent new opportunities to sell technology to the NHS. Suppliers will need to demonstrate that their products can reduce waiting times, increase staff capacity and improve patient outcomes.

A new public procurement definition of “UK supplier” is expected by January 2027, followed by a national procurement policy statement in March. Suppliers should prepare evidence of their UK contribution and social value. Whether the changes increase uptake of UK products, including medicines, will depend on how they are implemented.

Tax, VAT and operating costs

The Budget also promised simpler R&D tax claims, easing the administrative burden for companies.

It confirmed that a zero rate of VAT will apply to qualifying donations of medicines made from 23 June this year, including medicines donated for use in clinical trials and early and expanded access schemes. There has been broad industry support for this measure, noting that it is a significant win for patients.

The government intends to amend VAT rules for medical deputies to restore their "previously intended" treatment, from 1 May 2027. From April 2027, the cross-border services reverse charge will also be restricted to VAT-registered businesses, with overseas suppliers serving non-registered UK businesses required to account for VAT in the normal way. Alongside the minimum wage increases from April 2027, these changes reinforce the need for healthcare and care providers to review staffing budgets, margins and contractual mechanisms for reflecting cost increases.

Investment, founders and employee incentives

The British Business Bank will receive £5 billion of additional capacity, including £1.4 billion in commercial equity commitments and £450 million for a new venture debt product. This could broaden financing options for life sciences scale-ups, although access will depend on individual funding programmes and investment criteria.

From 6 April 2027, a new founders’ relief will offer qualifying entrepreneurs a 10% capital gains tax rate on up to £10 million of lifetime gains. The business asset disposal relief lifetime limit will fall to £500,000. Founders and investors should assess eligibility before factoring the changes into exit plans.

The individual option limit under the Company Share Option Plan, to be known as EMI2, will double to £120,000, with the exercise period to be extended to 15 years from 6 April 2027. Businesses will be considering how these changes could support recruitment and retention over lengthy development cycles, along with the broad range of tax and employee incentives measures in the Budget. 

Immigration and international recruitment

Planned reforms include expanding global talent host organisations, extending high-potential individual eligibility to the top 150 institutions and two-year graduate visas for qualifying universities. These could widen recruitment options for research-intensive businesses.

Legislation is also intended to ensure employers’ payments of immigration skills charges and certificate of sponsorship fees are not taxable benefits for payments from 28 October this year. Continued tightening for low- and medium-skilled individuals means workforce planning remains particularly important for healthcare and care providers.

Osborne Clarke comment

The measures in this Budget support the direction of the UK government's life sciences sector plan, which seeks to position the UK as Europe's leading life sciences economy by 2030 and the third globally, behind the US and China, by 2035. 

These measures can help strengthen the UK's position in an increasingly competitive market. The test will be whether they can enable companies to scale in the UK, attract manufacturing investment and help innovative products and medicines reach patients faster. Financial support for R&D clusters, manufacturing and AI addresses important parts of this challenge. Additional capacity for the British Business Bank and longer-term employee incentives could also help bridge the gap between discovery and commercialisation.

The uptake of innovation across the NHS will be a key measure of success. Robotics and AI procurement initiatives create promising opportunities, with successful pilots and faster authorisation providing a foundation for wider adoption. Clear pathways from evidence generation to procurement can help suppliers bring innovations to the NHS, while adequate funding, workforce capacity and infrastructure can help providers put new technologies into practice.

Businesses across the sector will be looking to assess eligibility, implementation dates and the detail of the proposed reforms before committing to investment or workforce decisions. They will also want to test investment plans against financing needs, adoption timelines and operating costs to identify where the measures can best support their growth.

* This article is current as of the date of its publication and does not necessarily reflect the present state of the law or relevant regulation.

Connect with one of our experts

Interested in hearing more from Osborne Clarke?